Sl03-Ohd-102- Phase 1 Dose Escalation Study Of The Agonist Redirected Checkpoint, Sl-172154 (Sirpα-Fc-Cd40l), Administered Intratumorally In Subjects With Cutaneous Squamous Cell Carcinoma Or Squamous Cell Carcinoma Of The Head And Neck
Posted Date: Jan 18, 2021
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Head and Neck Cancer, Oncology
- Type of Study: Drug
This is a Phase 1 open-label, multi-center, dose-escalation study to evaluate the safety, PK, anti-tumor activity, and pharmacodynamic effects of SL-172154 administered by intratumoral injection in subjects with cutaneous squamous cell carcinoma (CSCC) or squamous cell carcinoma of the head and neck (SCCHN). The primary outcomes measured will be the maximum tolerated dosage and the incidences of adverse events.
Criteria:
To Be Eligible: Must Have Histologically Confirmed Diagnosis Of An Unresectable Or Recurrent, Locally Advanced Or Metastatic Cutaneous Squamous Cell Carcinoma Or Squamous Cell Carcinoma Of The Head And Neck, Ecog 0-1, Life Expectancy >12 Weeks, Adequate Organ Function, No Autoimmune Disease, No Other Concurrent Maligancy, No Hypersensitivity To Study Drugs/Components, No Other Significant Medical History Or Active Infection That May Impact Safety On Study
Keywords:
Hnscc, Head And Neck Cancer
For More Information:
Uc Cancer Center
513-584-7658
cancer@uchealth.com